retatrutide triple agonist obesity Eli Lilly and Company's agonist, retatrutide, successful in two additional phase 3 trials, delivering significant improvements in weight and A1C Incretin triple agonist retatrutide (LY3437943)
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14

























